EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma

Lemeng Feng, Shirui Dai, Cheng Zhang, Wulong Zhang, Weiming Zhu, Chao Wang, Ye He, Weitao Song

Scientific Reports · 2024

DOI: 10.1038/s41598-024-54075-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Lemeng Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008,…. Hauptthemen laut MEDLINE: Retinal Ganglion Cells, Glaucoma. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Fund of China, Hunan Provincial Health Commission, Hunan Provincial Nature Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is a prevalent cause of blindness globally, characterized by the progressive degeneration of retinal ganglion cells (RGCs). Among various factors, glutamate excitotoxicity stands out as a significant contributor of RGCs loss in glaucoma. Our study focused on Ripa-56 and its protective effect against NMDA-induced retinal damage in mice, aiming to delve into the potential underlying mechanism. The R28 cells were categorized into four groups: glutamate (Glu), Glu + Ripa-56, Ripa-56 and Control group. After 24 h of treatment, cell death was assessed by PI / Hoechst staining. Mitochondrial membrane potential changes, apoptosis and reactive oxygen species (ROS) production were analyzed using flow cytometry. The alterations in the expression of RIP-1, p-MLKL, Bcl-2, BAX, Caspase-3, Gpx4 and SLC7A11 were examined using western blot analysis. C57BL/6j mice were randomly divided into NMDA, NMDA + Ripa-56, Ripa-56 and control groups. Histological changes in the retina were evaluated using hematoxylin and eosin (H&E) staining. RGCs survival and the protein expression changes of RIP-1, Caspase-3, Bcl-2, Gpx4 and SLC7A11 were observed using immunofluorescence. Ripa-56 exhibited a significant reduction in the levels of RIP-1, p-MLKL, Caspase-3, and BAX induced by glutamate, while promoting the expression of Bcl-2, Gpx-4, and SLC7A1 in the Ripa-56-treated group. In our study, using an NMDA-induced normal tension glaucoma mice model, we employed immunofluorescence and H&E staining to observe that Ripa-56 treatment effectively ameliorated retinal ganglion cell loss, mitigating the decrease in retinal ganglion cell layer and bipolar cell layer thickness caused by NMDA. In this study, we have observed that Ripa-56 possesses remarkable anti- necroptotic, anti-apoptotic and anti-ferroptosis properties. It demonstrates the ability to combat not only glutamate-induced excitotoxicity in R28 cells, but also NMDA-induced retinal excitotoxicity in mice. Therefore, Ripa-56 could be used as a potential retinal protective agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Ganglion CellsGlaucomaAnimalsMiceCaspase 3N-MethylaspartateGlutamic Acidbcl-2-Associated X ProteinMice, Inbred C57BLRetinaApoptosis

Stichwörter der Autor:innen

ApoptosisFerroptosisGlaucomaGlutamateNecroptosisRipa-56

Substanzen

Caspase 3N-MethylaspartateGlutamic Acidbcl-2-Associated X Protein

Autor:innen und Institutionen

  • National Clinical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China.
  • Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
  • Hunan Key Laboratory of Ophthalmology, Changsha, Hunan, 410008, People's Republic of China.
  • Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China.
  • Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, People's Republic of China.
  • National Clinical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China. wtsong1980@126.com.

Förderung

  • National Nature Science Fund of China
  • Hunan Provincial Health Commission
  • Hunan Provincial Nature Science Fund
  • National Key R&D Program of China

Zitieren

APA

Feng, L., Dai, S., Zhang, C., Zhang, W., Zhu, W., Wang, C., He, Y., & Song, W. (2024). Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma. Scientific Reports. https://doi.org/10.1038/s41598-024-54075-z

Vancouver

Feng L, Dai S, Zhang C, Zhang W, Zhu W, Wang C, et al. Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma. Scientific Reports. 2024. doi:10.1038/s41598-024-54075-z

BibTeX
@article{Feng2024,
  author = {Feng, Lemeng and Dai, Shirui and Zhang, Cheng and Zhang, Wulong and Zhu, Weiming and Wang, Chao and He, Ye and Song, Weitao},
  title = {Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma},
  journal = {Scientific Reports},
  year = {2024},
  doi = {10.1038/s41598-024-54075-z}
}
Kostenlos starten →